WO2008033891A3 - Azonafide derived tumor and cancer targeting compounds - Google Patents

Azonafide derived tumor and cancer targeting compounds Download PDF

Info

Publication number
WO2008033891A3
WO2008033891A3 PCT/US2007/078233 US2007078233W WO2008033891A3 WO 2008033891 A3 WO2008033891 A3 WO 2008033891A3 US 2007078233 W US2007078233 W US 2007078233W WO 2008033891 A3 WO2008033891 A3 WO 2008033891A3
Authority
WO
WIPO (PCT)
Prior art keywords
azonafide
derived tumor
cancer targeting
targeting compounds
compound
Prior art date
Application number
PCT/US2007/078233
Other languages
French (fr)
Other versions
WO2008033891A2 (en
Inventor
Nadya I Tarasova
Marcin Dyba
Christopher J Michejda
Original Assignee
Us Gov Health & Human Serv
Michejda Maria
Nadya I Tarasova
Marcin Dyba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Michejda Maria, Nadya I Tarasova, Marcin Dyba filed Critical Us Gov Health & Human Serv
Priority to EP07842310.0A priority Critical patent/EP2069308B1/en
Priority to US12/441,029 priority patent/US8008316B2/en
Publication of WO2008033891A2 publication Critical patent/WO2008033891A2/en
Publication of WO2008033891A3 publication Critical patent/WO2008033891A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

An azonafide-based compound of Formula I, a composition comprising the compound, and a method of using the compound to deliver a cytotoxic azonafide derivative to a cell, as well as related compounds and methods for the use thereof to prepare an azonafide-based compound of Formula I.
PCT/US2007/078233 2006-09-12 2007-09-12 Azonafide derived tumor and cancer targeting compounds WO2008033891A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07842310.0A EP2069308B1 (en) 2006-09-12 2007-09-12 Azonafide derived tumor and cancer targeting compounds
US12/441,029 US8008316B2 (en) 2006-09-12 2007-09-12 Azonafide derived tumor and cancer targeting compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84402706P 2006-09-12 2006-09-12
US60/844,027 2006-09-12

Publications (2)

Publication Number Publication Date
WO2008033891A2 WO2008033891A2 (en) 2008-03-20
WO2008033891A3 true WO2008033891A3 (en) 2008-08-28

Family

ID=39184536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078233 WO2008033891A2 (en) 2006-09-12 2007-09-12 Azonafide derived tumor and cancer targeting compounds

Country Status (3)

Country Link
US (1) US8008316B2 (en)
EP (1) EP2069308B1 (en)
WO (1) WO2008033891A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103497235B (en) * 2013-07-18 2015-03-25 广东药学院 Small molecular peptide probe and preparation method and application thereof
MA41866A (en) 2015-03-31 2018-02-06 Massachusetts Gen Hospital SELF-ASSEMBLING MOLECULES FOR TARGETED DRUG DELIVERY
CN110475569B (en) 2017-02-28 2023-11-21 第一三共株式会社 EGFR-TKI-resistant non-small cell lung cancer therapeutic agent and application of anti-HER 3 antibody-drug conjugate
WO2020059772A1 (en) 2018-09-20 2020-03-26 第一三共株式会社 Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate
CN111333622B (en) * 2018-12-18 2022-08-09 中国科学院大连化学物理研究所 High-brightness and high-stability fluorescent dye containing active ester and synthesis and application thereof
EP4183799A1 (en) 2020-07-17 2023-05-24 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
WO2023179205A1 (en) * 2022-03-23 2023-09-28 湘北威尔曼制药股份有限公司 Diimide derivative, preparation method therefor and use thereof
WO2023196958A2 (en) * 2022-04-07 2023-10-12 Oncolinx Pharmaceuticals Tumor and cancer targeting compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000281A1 (en) * 1990-06-26 1992-01-09 Research Corporation Technologies, Inc. 1,2-dihydro-3h-dibenzisoquinoline-1,3-dione anticancer agents
US5703089A (en) * 1994-04-28 1997-12-30 Knoll Aktiengesellschaft Dihydrodibenzisoquinolinediones
WO2006060533A2 (en) * 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635506A (en) 1990-06-26 1997-06-03 Research Corporation Technologies, Inc. 1, 2-dihydro-3H-dibenzisoquinoline-1,3-dione anticancer agents
US20050171014A1 (en) 2002-02-27 2005-08-04 Government Of The United States Of America, Represented By The Secretary, Department Of Health Conjugates of ligand linker and cytotoxic agent and related composition and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000281A1 (en) * 1990-06-26 1992-01-09 Research Corporation Technologies, Inc. 1,2-dihydro-3h-dibenzisoquinoline-1,3-dione anticancer agents
US5703089A (en) * 1994-04-28 1997-12-30 Knoll Aktiengesellschaft Dihydrodibenzisoquinolinediones
WO2006060533A2 (en) * 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMI S M ET AL: "2-Substituted 1,2-Dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of Antitumor Agents", 1 January 1993, JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, PAGE(S) 765 - 770, ISSN: 0022-2623, XP002177481 *

Also Published As

Publication number Publication date
US8008316B2 (en) 2011-08-30
US20100120817A1 (en) 2010-05-13
WO2008033891A2 (en) 2008-03-20
EP2069308A2 (en) 2009-06-17
EP2069308B1 (en) 2017-03-29

Similar Documents

Publication Publication Date Title
WO2008033891A3 (en) Azonafide derived tumor and cancer targeting compounds
WO2008019025A3 (en) Isoform-selective hdac inhibitors
WO2012030685A3 (en) Indazole derivatives useful as erk inhibitors
WO2011033265A8 (en) Pharmaceutical compounds
MEP23808A (en) Pyridine[3,4-b]pyrazinones
WO2011031554A3 (en) Heterocyclic compounds as janus kinase inhibitors
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2010108074A3 (en) Inhibitors of pi3 kinase
WO2007135527A3 (en) Benzimidazolyl compounds
MX2011012198A (en) Aryl pyridine as aldosterone synthase inhibitors.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
TN2012000248A1 (en) Novel spiropiperidine compounds
WO2006116733A3 (en) Protein kinase inhibitors
AU2008246443A8 (en) 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
MX2009003081A (en) Pyrrole derivatives useful for the treatment of cytokine-mediated diseases.
WO2008075192A3 (en) Targeting and therapeutic compounds and gas-filled microvesicles comprising said com ounds
WO2011058027A3 (en) N-9-substituted purine compounds, compositions and methods of use
ZA200906648B (en) Pyrido [2,3-D] pyramidin-7-one compounds as inhibitors of P13K-alpha for the treatment of cancer
WO2007081694A3 (en) Derivatives of sulindac, use thereof and preparation thereof
WO2009013545A3 (en) Chemical compounds
MX2009005071A (en) Substituted pyrazole and triazole compounds as ksp inhibitors.
WO2009105969A8 (en) Epothilone analogues, their pharmaceutical compositions, their use and their preparations
WO2011079230A3 (en) Heterocyclic compounds as janus kinase inhibitors
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2007842310

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007842310

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12441029

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842310

Country of ref document: EP

Kind code of ref document: A2